Janssen, a subsidiary of Johnson & Johnson, announced that it has selected INVEGA™ as the brand name for paliperidone extended release tablets, the company's investigational oral atypical antipsychotic. The company is seeking approval from the U.S. Food and Drug Administration (FDA) to market INVEGA™ for the treatment of schizophrenia.
» Search Branding-Specific Tags: Schizophrenia - Drug Name - Drug Naming
» Johnson & Johnson


Comments